A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Public ClinicalTrials.gov record NCT02205333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
Study identification
- NCT ID
- NCT02205333
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 48 participants
Conditions and interventions
Conditions
Interventions
- MEDI6469 Monotherapy Biological
- MEDI6469 Plus Durvalumab Biological
- MEDI6469 Plus Tremelimumab Biological
- MEDI6469 plus Rituximab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 12, 2014
- Primary completion
- Apr 7, 2016
- Completion
- Apr 7, 2016
- Last update posted
- Jun 27, 2017
2014 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Scottsdale | Arizona | 85259 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Washington D.C. | District of Columbia | 20007 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Chicago | Illinois | 60611 | — |
| Research Site | Detroit | Michigan | 48202 | — |
| Research Site | Las Vegas | Nevada | 89169 | — |
| Research Site | Hackensack | New Jersey | 7601 | — |
| Research Site | Huntersville | North Carolina | 28078 | — |
| Research Site | Portland | Oregon | 97213 | — |
| Research Site | Memphis | Tennessee | 38120 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02205333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2017 · Synced May 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02205333 live on ClinicalTrials.gov.